杉本 真也 (スギモト シンヤ)

Sugimoto, Shinya

写真a

所属(所属キャンパス)

医学部 坂口光洋記念講座(オルガノイド医学) (信濃町)

職名

助教(有期)

学歴 【 表示 / 非表示

  • 2003年04月
    -
    2009年03月

    慶應義塾, 医学部

    大学, 卒業

  • 2014年04月
    -
    2018年03月

    慶應義塾, 医学研究科医学研究系専攻

    大学院, 修了, 博士

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾, 課程, 2018年03月

    Reconstruction of the Human Colon Epithelium In Vivo

 

研究分野 【 表示 / 非表示

  • 消化器内科学

研究キーワード 【 表示 / 非表示

  • オルガノイド

  • 炎症性腸疾患

  • 腸管上皮幹細胞

 

論文 【 表示 / 非表示

  • Wnt Signaling Shapes the Histological Variation in Diffuse Gastric Cancer.

    Togasaki K, Sugimoto S, Ohta Y, Nanki K, Matano M, Takahashi S, Fujii M, Kanai T, Sato T

    Gastroenterology 2020年11月

    ISSN  0016-5085

  • An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.

    Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T

    Cell (Cell)  183 ( 5 ) 1420 - 1435.e21 2020年10月

    ISSN  0092-8674

     概要を見る

    © 2020 Elsevier Inc. Gastroenteropancreatic (GEP) neuroendocrine neoplasm (NEN) that consists of neuroendocrine tumor and neuroendocrine carcinoma (NEC) is a lethal but under-investigated disease owing to its rarity. To fill the scarcity of clinically relevant models of GEP-NEN, we here established 25 lines of NEN organoids and performed their comprehensive molecular characterization. GEP-NEN organoids recapitulated pathohistological and functional phenotypes of the original tumors. Whole-genome sequencing revealed frequent genetic alterations in TP53 and RB1 in GEP-NECs, and characteristic chromosome-wide loss of heterozygosity in GEP-NENs. Transcriptome analysis identified molecular subtypes that are distinguished by the expression of distinct transcription factors. GEP-NEN organoids gained independence from the stem cell niche irrespective of genetic mutations. Compound knockout of TP53 and RB1, together with overexpression of key transcription factors, conferred on the normal colonic epithelium phenotypes that are compatible with GEP-NEN biology. Altogether, our study not only provides genetic understanding of GEP-NEN, but also connects its genetics and biological phenotypes. Gastroenteropancreatic neuroendocrine neoplasms are a rare but lethal cancer with a scarcity of clinically relevant models. Kawasaki et al. establish and characterize 25 organoid lines to identify molecular subtypes with genotype-phenotype mapping.

  • Water-assisted colonoscopy: an international modified Delphi review on definitions and practice recommendations.

    Cadoni S, Ishaq S, Hassan C, Falt P, Fuccio L, Siau K, Leung JW, Anderson J, Binmoeller KF, Radaelli F, Rutter MD, Sugimoto S, Muhammad H, Leung FW, International WATERS and modified Delphi respondents groups.

    Gastrointestinal endoscopy 2020年10月

    ISSN  0016-5107

  • Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis

    Naganuma M., Kobayashi T., Nasuno M., Motoya S., Kato S., Matsuoka K., Hokari R., Watanabe C., Sakamoto H., Yamamoto H., Sasaki M., Watanabe K., Iijima H., Endo Y., Ichikawa H., Ozeki K., Tanida S., Ueno N., Fujiya M., Sako M., Takeuchi K., Sugimoto S., Abe T., Hibi T., Suzuki Y., Kanai T.

    Clinical Gastroenterology and Hepatology (Clinical Gastroenterology and Hepatology)  18 ( 5 ) 1102 - 1111.e5 2020年05月

    ISSN  15423565

     概要を見る

    © 2020 AGA Institute Background & Aims: We compared the diagnostic accuracy of the fecal calprotectin (FCP) test vs the fecal immunochemical blood test (FIT) in determining the endoscopic severity and predicting outcomes of patients with ulcerative colitis (UC). Methods: We performed a nationwide study of 879 patients with UC, enrolled at medical centers across Japan, from March 2015 to March 2017. We collected data on fecal biomarkers, endoscopic severities, and other clinical indices from Cohort 1 (n = 427) and assessed the diagnostic accuracy of FCP measurement and FIT results in determining clinical severity, based on Mayo score, and endoscopic remission, based on Mayo endoscopic sub-score (MES) or UC endoscopic index of severity. We also followed 452 patients in clinical remission from UC (Cohort 2) for 12 months and evaluated the associations of FCP levels and FIT results with clinical recurrence. Results: The levels of FCP and FIT each correlated with the MES and UC endoscopic index of severity. There were no significant differences in the areas under the curve of FCP vs FIT in distinguishing patients with MES≤1 from those with MES≥2 (P = .394) or in distinguishing patients with MES=0 from those with MES≥1 (P = .178). Among 405 patients in clinical remission at baseline, 38 (9.4%) had UC recurrences within 3 months and 90 (22.2%) had recurrences within 12 months. FCP≥146 mg/kg (hazard ratio [HR], 4.83; 95% confidence interval [CI], 2.80-8.33) and FIT≥77 ng/mL (HR, 2.92; 95% CI, 1.76-4.83) were independently associated with clinical recurrence within 12 months. UC recurred within 12 months in 69% of patients with levels of FCP≥146 mg/kg and FIT ≥77 ng/mL; this value was significantly higher than the rate of recurrence in patients with levels of FCP≥146 mg/kg and FIT <77 ng/mL (31.5%, P < .001) or patients with levels of FCP<146 mg/kg and FIT ≥77 ng/mL (30.0%, P < .001). Conclusion: In a nationwide study of patients with UC in Japan, we found that the level of FCP and FIT could each identify patients with endoscopic markers of disease severity (MES≥2). The combination of FCP and FIT results can identify patients in remission who are at risk for disease recurrence. Clinical Trials Registry no: UMIN000017650 (http://www.umin.ac.jp/ctr/)

  • Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study

    Naganuma M., Sugimoto S., Fukuda T., Mitsuyama K., Kobayashi T., Yoshimura N., Ohi H., Tanaka S., Andoh A., Ohmiya N., Saigusa K., Yamamoto T., Morohoshi Y., Ichikawa H., Matsuoka K., Hisamatsu T., Watanabe K., Mizuno S., Abe T., Suzuki Y., Kanai T., Naganuma M., Nakazato Y., Teratani T., Ogata H., Iwao Y., Yamasaki H., Toyonaga T., Nakano M., Hibi T., Sameshima Y., Hayashi R., Ueno Y., Bamba S., Watanabe M., Nakazawa A., Koike Y., Imai J., Shimoyama T., Takeuchi K., Nagasaka M., Kitano A., Ashizuka S., Inatsu H., Onodera K., Nakase H., Kitamura K., Ikeya K., Hanai H., Watanabe C., Hokari R., Hirai F., Naito Y., Hoshi N., Kinjo F., Ishiguro Y., Sasaki M., Matsumoto T., Sano F., Roberts R., Suda W., Hattori M., Fukuda S., Hirayama A.

    Journal of Gastroenterology (Journal of Gastroenterology)  55 ( 2 ) 169 - 180 2020年02月

    ISSN  09441174

     概要を見る

    © 2019, Japanese Society of Gastroenterology. Background: We recently reported the efficacy of indigo naturalis (IN) in patients with active ulcerative colitis (UC) in a randomized controlled trial (INDIGO study). However, few studies have been conducted to investigate whether IN is effective even in treatment-refractory cases, such as in those with steroid dependency and anti-TNF refractoriness. Methods: In the INDIGO study, 86 patients with active UC were randomly assigned to an IN group (0.5–2.0 g daily) or placebo group. The rate of clinical response (CR), mucosal healing (MH), and change in fecal calprotectin (FCP) levels was compared between refractory [patients with steroid-dependent disease, previous use of anti-TNF-α, and concomitant use of immunomodulators (IM)] and non-refractory patients. We also analyzed factors predicting CR and MH at week 8. Results: The rates of CR of IN group were significantly higher than placebo group, even in patients with steroid-dependent disease (p < 0.001), previous use of anti-TNF-α (p = 0.002), and concomitant use of IM (p = 0.013). The rates of MH in IN group were significantly higher than in placebo group in patients with steroid-dependent disease (p = 0.009). In the IN group, median FCP levels, at week 8, were significantly lower than baseline in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α (p < 0.001, respectively). Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. Conclusions: In a sub-analysis of data from a randomized placebo-controlled trial, we found that IN may be useful even in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α.

全件表示 >>

総説・解説等 【 表示 / 非表示

競争的資金等の研究課題 【 表示 / 非表示

  • 小腸上皮オルガノイドにより創出した移植グラフトの機能解析

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 杉本 真也, 基盤研究(B), 補助金,  代表

  • 腸管AhRワールドの解明

    2019年02月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 金井 隆典, 国際共同研究加速基金(国際共同研究強化(B)), 分担

  • 腸管上皮-間質ニッチの包括的理解と自己補完的組織培養技術の確立

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 杉本 真也, 特別研究員奨励費, 補助金,  代表

受賞 【 表示 / 非表示

  • 若手奨励賞

    2019年11月, JDDW

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 東京都医師会医学研究賞奨励賞

    2019年03月, 東京都医師会

    受賞区分: 出版社・新聞社・財団等の賞

  • 井上研究奨励賞

    2019年02月, 井上科学振興財団

    受賞区分: 出版社・新聞社・財団等の賞

  • 三四会奨励賞

    2018年06月, 慶應義塾大学医学部三四会

    受賞区分: 塾内表彰等

  • 日本消化管学会奨励賞

    2017年02月, 日本消化管学会

    受賞区分: 学会誌・学術雑誌による顕彰

全件表示 >>